Cargando…

Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry

Current guidelines recommend BRCA1 and BRCA2 genetic testing for individuals with a personal or family history of certain cancers. Three BRCA1/2 founder variants — 185delAG (c.68_69delAG), 5382insC (c.5266dupC), and 6174delT (c.5946delT) — are common in the Ashkenazi Jewish population. We characteri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tennen, Ruth I., Laskey, Sarah B., Koelsch, Bertram L., McIntyre, Matthew H., Tung, Joyce Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203114/ https://www.ncbi.nlm.nih.gov/pubmed/32376921 http://dx.doi.org/10.1038/s41598-020-63466-x

Ejemplares similares

Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer
por: Hamel, Nancy, et al.
Publicado: (2003)

BRCA1 and BRCA2 Mutations Other Than the Founder Alleles Among Ashkenazi Jewish in the Population of Argentina
por: Solano, Angela R., et al.
Publicado: (2018)

Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk
por: Hamada, Tsuyoshi, et al.
Publicado: (2019)

How old is this mutation? - a study of three Ashkenazi Jewish founder mutations
por: Greenwood, Celia MT, et al.
Publicado: (2010)

Counting the Founders: The Matrilineal Genetic Ancestry of the Jewish Diaspora
por: Behar, Doron M., et al.
Publicado: (2008)

Y chromosome haplogroups and prostate cancer in populations of European and Ashkenazi Jewish ancestry
por: Wang, Zhaoming, et al.
Publicado: (2012)

Beyond the “Jewish panel”: the importance of offering expanded carrier screening to the Ashkenazi Jewish population
por: Dolitsky, Shelley, et al.
Publicado: (2020)

Carrier screening in individuals of Ashkenazi Jewish descent
por: Gross, Susan J., et al.
Publicado: (2008)

Hereditary cancer screening: Case reports and review of literature on ten Ashkenazi Jewish founder mutations
por: Cox, Devin M., et al.
Publicado: (2018)

Ashkenazi Jewish Centenarians Do Not Demonstrate Enrichment in Mitochondrial Haplogroup J
por: Shlush, Liran I., et al.
Publicado: (2008)

Genetic architecture of prostate cancer in the Ashkenazi Jewish population
por: Vijai, J, et al.
Publicado: (2011)

High mammographic density in women of Ashkenazi Jewish descent
por: Caswell, Jennifer L, et al.
Publicado: (2013)

The time and place of European admixture in Ashkenazi Jewish history
por: Xue, James, et al.
Publicado: (2017)

The frequency of the predominant Jewish mutations in BRCA1 and BRCA2 in unselected Ashkenazi colorectal cancer patients
por: Chen-Shtoyerman, R, et al.
Publicado: (2001)

Implications for health and disease in the genetic signature of the Ashkenazi Jewish population
por: Guha, Saurav, et al.
Publicado: (2012)

Genetic Complexity of Crohn’s Disease in Two Large Ashkenazi Jewish Families
por: Levine, Adam P., et al.
Publicado: (2016)

Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population
por: Rivas, Manuel A., et al.
Publicado: (2018)

The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel
por: Vazina, A, et al.
Publicado: (2000)

Population Testing for Cancer Predisposing BRCA1/BRCA2 Mutations in the Ashkenazi-Jewish Community: A Randomized Controlled Trial
por: Manchanda, Ranjit, et al.
Publicado: (2014)

Cost-effectiveness of Population Screening for BRCA Mutations in Ashkenazi Jewish Women Compared With Family History–Based Testing
por: Manchanda, Ranjit, et al.
Publicado: (2014)

Identifying high-impact variants and genes in exomes of Ashkenazi Jewish inflammatory bowel disease patients
por: Wu, Yiming, et al.
Publicado: (2023)

Ashkenazi Jewish Origin Protects Against Formation of Antibodies to Infliximab and Therapy Failure
por: Ungar, Bella, et al.
Publicado: (2015)

Correction: Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population
por: Rivas, Manuel A., et al.
Publicado: (2019)

A collaborative genetic carrier screening model for the British Ashkenazi Jewish community
por: Ziff, Monica, et al.
Publicado: (2021)

Rare coding variant analysis in a large cohort of Ashkenazi Jewish families with inflammatory bowel disease
por: Schiff, E. R., et al.
Publicado: (2018)

Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA)
por: Apicella, Carmel, et al.
Publicado: (2003)

A novel de novo PAX6 mutation in an Ashkenazi-Jewish family with aniridia
por: Bandah, Dikla, et al.
Publicado: (2008)

A New Look at Familial Risk of Inflammatory Bowel Disease in the Ashkenazi Jewish Population
por: Schiff, Elena R., et al.
Publicado: (2018)

Attitudes and interest in incorporating BRCA1/2 cancer susceptibility testing into reproductive carrier screening for Ashkenazi Jewish men and women
por: Hardy, Melanie W., et al.
Publicado: (2022)

Evaluation of 22 genetic variants with Crohn's Disease risk in the Ashkenazi Jewish population: a case-control study
por: Peter, Inga, et al.
Publicado: (2011)

Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer.
por: Lehrer, S., et al.
Publicado: (1998)

Dissecting the genetic heterogeneity of myopia susceptibility in an Ashkenazi Jewish population using ordered subset analysis
por: Simpson, Claire L., et al.
Publicado: (2011)

Genome-Wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish population
por: Liu, Xinmin, et al.
Publicado: (2011)

A Genome-Wide Scan of Ashkenazi Jewish Crohn's Disease Suggests Novel Susceptibility Loci
por: Kenny, Eimear E., et al.
Publicado: (2012)

Breast cancer mortality among Ashkenazi Jewish women in São Paulo and Porto Alegre, Brazil
por: Koifman, Sergio, et al.
Publicado: (2001)

Evaluation of genetic alterations in hereditary cancer susceptibility genes in the Ashkenazi Jewish women community of Mexico
por: Díaz-Velásquez, Clara Estela, et al.
Publicado: (2023)

Differences in MS clinical and epidemiological characteristics between Ashkenazi and non-Ashkenazi Jewish patients in Israel: a retrospective single center study
por: Karni, Arnon, et al.
Publicado: (2022)

Prevalence of 185delAG and 5382insC mutations in BRCA1, and 6174delT in BRCA2 in women of Ashkenazi Jewish origin in southern Brazil
por: Dillenburg, Crisle Vignol, et al.
Publicado: (2012)

Identification of a novel pathogenic OTOF variant causative of nonsyndromic hearing loss with high frequency in the Ashkenazi Jewish population
por: Fedick, Anastasia M, et al.
Publicado: (2016)

Identification of Novel and Recurrent Variants in MYO15A in Ashkenazi Jewish Patients With Autosomal Recessive Nonsyndromic Hearing Loss
por: Booth, Kevin T., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m1o65oopbsp53dfrg3gjh9m4mp